Automated Breast Ultrasound Systems Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

The Global Automated Breast Ultrasound Systems Market was valued at USD 2.2 billion in 2024 and is estimated to grow at a CAGR of 16.7% to reach USD 10.1 billion by 2034. Rising breast cancer rates across the globe, growing emphasis on early detection, strong public health awareness, and government-backed screening initiatives are among the core factors driving this market forward. With rapid advances in medical imaging and diagnostic technology, automated breast ultrasound systems are gaining ground as essential tools in breast cancer screening, especially among women with dense breast tissue.

Automated breast ultrasound systems, or ABUS, offer advanced 3D visualization of the entire breast, providing consistent and standardized imaging without relying heavily on the skill of the operator. Their implementation is rapidly increasing in hospitals, imaging centers, and specialized breast care facilities due to their ability to enhance detection accuracy. By capturing high-resolution images across tissue layers, these systems support early diagnosis and improve patient outcomes. As health organizations continue prioritizing early-stage cancer identification, the integration of ABUS alongside other imaging methods becomes even more important. The focus on dense breast screening and AI-enhanced diagnostics is expected to drive demand and adoption worldwide.

In 2024, the ABUS category held the largest market value at USD 1.4 billion and will reach USD 6.5 billion by 2034, growing at a CAGR of 16.9%. Its leadership in the market stems from increasing demand for AI-powered diagnostics, wider awareness of breast cancer risks, and the growing use of these systems across healthcare environments for thorough screening and detailed analysis. ABUS delivers full 3D breast imaging, enabling radiologists to identify abnormalities that may go unnoticed with conventional mammography. Its high clarity reduced human error, and standardization has made it a key asset in breast cancer detection for patients with dense breast composition.

The hospitals segment held a 45.1% share in 2024. These facilities are equipped with advanced diagnostic technology and have access to skilled professionals, making them leading adopters of ABUS. As central hubs for cancer screening, diagnosis, and treatment, hospitals handle high patient volumes and benefit from public health screening programs, further promoting the use of automated ultrasound systems. The integration of ABUS into broader diagnostic workflows allows healthcare providers to offer more complete and efficient breast care services.

United States Automated Breast Ultrasound Systems Market reached USD 758.3 million in 2024. This growth is closely tied to the increasing incidence of breast cancer across the country, which has led to a surge in demand for precise, early-stage diagnostic tools. The U.S. healthcare ecosystem also benefits from a favorable regulatory environment, widespread public education on cancer screening, and strong investments in medical technology innovation. These factors create a solid foundation for ABUS adoption and continued market expansion.

Key companies active in the Global Automated Breast Ultrasound Systems Market include Siemens Healthineers, SonoCine, Inc., Canon, GE Healthcare, Real Imaging, Seno Medical Instruments Inc., Hologic, Supersonic Imagine, Shantou Institute of Ultrasonic Instruments, Theraclion, Metritrack, QView Medical, Delphinus Medical Technologies, Koninklijke Philips, CapeRay Medical, and Hitachi. Companies operating in the automated breast ultrasound systems market are strengthening their presence through a combination of innovation, global expansion, and collaborative partnerships. Leading players are heavily investing in R&D to enhance image quality, reduce scan time, and integrate AI-based interpretation tools. To meet increasing demand in both developed and emerging markets, manufacturers are expanding their distribution networks and entering strategic alliances with hospitals and diagnostic chains. Many firms are working on gaining faster regulatory approvals to accelerate product rollouts, especially in high-burden regions.